Association Between Hypertensive Disorders of Pregnancy and Later Risk of Cardiomyopathy | Cardiology | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
American College of Obstetricians and GynecologistsTask Force on Hypertension in Pregnancy.  Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy.  Obstet Gynecol. 2013;122(5):1122-1131.PubMedGoogle ScholarCrossref
2.
Abalos  E, Cuesta  C, Grosso  AL, Chou  D, Say  L.  Global and regional estimates of preeclampsia and eclampsia: a systematic review.  Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1-7.PubMedGoogle ScholarCrossref
3.
Steegers  EA, von Dadelszen  P, Duvekot  JJ, Pijnenborg  R.  Pre-eclampsia.  Lancet. 2010;376(9741):631-644.PubMedGoogle ScholarCrossref
4.
Bello  N, Rendon  ISH, Arany  Z.  The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis.  J Am Coll Cardiol. 2013;62(18):1715-1723.PubMedGoogle ScholarCrossref
5.
Elkayam  U.  Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management.  J Am Coll Cardiol. 2011;58(7):659-670.PubMedGoogle ScholarCrossref
6.
Sliwa  K, Fett  J, Elkayam  U.  Peripartum cardiomyopathy.  Lancet. 2006;368(9536):687-693.PubMedGoogle ScholarCrossref
7.
Brown  MC, Best  KE, Pearce  MS, Waugh  J, Robson  SC, Bell  R.  Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis.  Eur J Epidemiol. 2013;28(1):1-19.PubMedGoogle ScholarCrossref
8.
McDonald  SD, Malinowski  A, Zhou  Q, Yusuf  S, Devereaux  PJ.  Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses.  Am Heart J. 2008;156(5):918-930.PubMedGoogle ScholarCrossref
9.
Lykke  JA, Langhoff-Roos  J, Sibai  BM, Funai  EF, Triche  EW, Paidas  MJ.  Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother.  Hypertension. 2009;53(6):944-951.PubMedGoogle ScholarCrossref
10.
Wikström  A-K, Haglund  B, Olovsson  M, Lindeberg  SN.  The risk of maternal ischaemic heart disease after gestational hypertensive disease.  BJOG. 2005;112(11):1486-1491.PubMedGoogle ScholarCrossref
11.
Bellamy  L, Casas  J-P, Hingorani  AD, Williams  DJ.  Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis.  BMJ. 2007;335(7627):974.PubMedGoogle ScholarCrossref
12.
Melchiorre  K, Sutherland  GR, Liberati  M, Thilaganathan  B.  Preeclampsia is associated with persistent postpartum cardiovascular impairment.  Hypertension. 2011;58(4):709-715.PubMedGoogle ScholarCrossref
13.
Melchiorre  K, Sutherland  GR, Baltabaeva  A, Liberati  M, Thilaganathan  B.  Maternal cardiac dysfunction and remodeling in women with preeclampsia at term.  Hypertension. 2011;57(1):85-93.PubMedGoogle ScholarCrossref
14.
Powe  CE, Levine  RJ, Karumanchi  SA.  Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease.  Circulation. 2011;123(24):2856-2869.PubMedGoogle ScholarCrossref
15.
Patten  IS, Rana  S, Shahul  S,  et al.  Cardiac angiogenic imbalance leads to peripartum cardiomyopathy.  Nature. 2012;485(7398):333-338.PubMedGoogle ScholarCrossref
16.
Tranquilli  AL, Dekker  G, Magee  L,  et al.  The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP.  Pregnancy Hypertens. 2014;4(2):97-104.PubMedGoogle Scholar
17.
Duckitt  K, Harrington  D.  Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies.  BMJ. 2005;330(7491):565.PubMedGoogle ScholarCrossref
18.
Elliott  P, Andersson  B, Arbustini  E,  et al.  Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.  Eur Heart J. 2008;29(2):270-276.PubMedGoogle ScholarCrossref
19.
Lange  T, Vansteelandt  S, Bekaert  M.  A simple unified approach for estimating natural direct and indirect effects.  Am J Epidemiol. 2012;176(3):190-195.PubMedGoogle ScholarCrossref
20.
Mosca  L, Benjamin  EJ, Berra  K,  et al; American Heart Association.  Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association.  J Am Coll Cardiol. 2011;57(12):1404-1423.PubMedGoogle ScholarCrossref
21.
Therneau  TM, Grambsch  PM, Fleming  TR.  Martingale-based residuals for survival models.  Biometrika. 1990;77(1):147-160.Google ScholarCrossref
22.
Melchiorre  K, Sharma  R, Thilaganathan  B.  Cardiovascular implications in preeclampsia: an overview.  Circulation. 2014;130(8):703-714.PubMedGoogle ScholarCrossref
23.
Melchiorre  K, Thilaganathan  B.  Maternal cardiac function in preeclampsia.  Curr Opin Obstet Gynecol. 2011;23(6):440-447.PubMedGoogle ScholarCrossref
24.
Melchiorre  K, Sutherland  G, Sharma  R, Nanni  M, Thilaganathan  B.  Mid-gestational maternal cardiovascular profile in preterm and term pre-eclampsia: a prospective study.  BJOG. 2013;120(4):496-504.PubMedGoogle ScholarCrossref
25.
Levine  RJ, Maynard  SE, Qian  C,  et al.  Circulating angiogenic factors and the risk of preeclampsia.  N Engl J Med. 2004;350(7):672-683.PubMedGoogle ScholarCrossref
26.
Levine  RJ, Lam  C, Qian  C,  et al; CPEP Study Group.  Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.  N Engl J Med. 2006;355(10):992-1005.PubMedGoogle ScholarCrossref
27.
Chaiworapongsa  T, Romero  R, Kim  YM,  et al.  Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia.  J Matern Fetal Neonatal Med. 2005;17(1):3-18.PubMedGoogle ScholarCrossref
28.
Chaiworapongsa  T, Romero  R, Espinoza  J,  et al.  Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia.  Am J Obstet Gynecol. 2004;190(6):1541-1547.PubMedGoogle ScholarCrossref
29.
Noori  M, Donald  AE, Angelakopoulou  A, Hingorani  AD, Williams  DJ.  Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.  Circulation. 2010;122(5):478-487.PubMedGoogle ScholarCrossref
30.
Rana  S, Powe  CE, Salahuddin  S,  et al.  Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia.  Circulation. 2012;125(7):911-919.PubMedGoogle ScholarCrossref
31.
ACOG Committee on Practice Bulletins—Obstetrics.  ACOG practice bulletin: diagnosis and management of preeclampsia and eclampsia.  Obstet Gynecol. 2002;99(1):159-167.PubMedGoogle ScholarCrossref
32.
Klemmensen  AK, Olsen  SF, Osterdal  ML, Tabor  A.  Validity of preeclampsia-related diagnoses recorded in a national hospital registry and in a postpartum interview of the women.  Am J Epidemiol. 2007;166(2):117-124.PubMedGoogle ScholarCrossref
33.
Wilkins-Haug  L, Celi  A, Thomas  A, Frolkis  J, Seely  EW.  Recognition by women’s health care providers of long-term cardiovascular disease risk after preeclampsia.  Obstet Gynecol. 2015;125(6):1287-1292.PubMedGoogle ScholarCrossref
Original Investigation
March 8, 2016

Association Between Hypertensive Disorders of Pregnancy and Later Risk of Cardiomyopathy

Author Affiliations
  • 1Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
  • 2Department of Obstetrics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark
  • 3Unit for Inherited Cardiac Diseases, The Heart Centre, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark
  • 4Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark
  • 5Department of Medicine, Stanford University School of Medicine, Stanford, California
JAMA. 2016;315(10):1026-1033. doi:10.1001/jama.2016.1869
Abstract

Importance  Women with hypertensive disorders of pregnancy, preeclampsia in particular, have an increased risk of cardiomyopathy during the peripartum period. Whether hypertensive disorders of pregnancy are also associated with cardiomyopathy later in life is unknown.

Objective  To determine whether hypertensive disorders of pregnancy are associated with cardiomyopathy beyond the peripartum period.

Design, Setting, and Participants  Nationwide register–based cohort study using Cox regression to compare rates of cardiomyopathy in women with and without a history of hypertensive disorders of pregnancy in a cohort of 1 075 763 women with at least 1 pregnancy ending in live birth or stillbirth in Denmark, 1978-2012, with follow-up through December 31, 2012.

Exposures  A hypertensive disorder of pregnancy (severe or moderate preeclampsia or gestational hypertension) registered in the National Patient Register.

Main Outcomes and Measures  Cardiomyopathy more than 5 months after delivery (outside the peripartum period) up to 34 years 7 months.

Result  The women in the primary cohort had 2 067 633 eligible pregnancies during the study period, 76 108 of which were complicated by a hypertensive disorder of pregnancy. During follow-up, 1577 women (mean age, 48.5 years at cardiomyopathy diagnosis; 2.6% with multiple pregnancies) developed cardiomyopathy. Compared with women with normotensive pregnancies (18 211 603 person-years of follow-up; n = 1408 cardiomyopathy events, 7.7/100 000 person-years [95% CI, 7.3-8.2]), women with a history of hypertensive disorders of pregnancy had significantly increased rates of cardiomyopathy (in 173 062 person-years of follow-up among women with severe preeclampsia, n = 27 cardiomyopathy events; 15.6/100 000 person-years [95% CI, 10.7-22.7]; adjusted hazard ratio [HR], 2.20 [95% CI, 1.50-3.23]; in 697 447 person-years of follow-up among women with moderate preeclampsia, n = 102 cardiomyopathy events; 14.6/100 000 person-years [95% CI, 12.0-17.8]; adjusted HR, 1.89 [95% CI, 1.55-2.23]; in 213 197 person-years of follow-up among women with gestational hypertension, n = 40 cardiomyopathy events; 17.3/100 000 person-years [95% CI, 12.7-23.6]; adjusted HR, 2.06 [95% CI, 1.50-2.82]). These increases persisted more than 5 years after the latest pregnancy. Mediation analyses suggested that only about 50% of the association was an indirect association through postpregnancy chronic hypertension. In this cohort, 11% of all cardiomyopathy events occurred in women with a history of hypertensive disorders of pregnancy.

Conclusions and Relevance  Women with a history of hypertensive disorders of pregnancy, compared with women without such a history, had a small but statistically significant increased risk of cardiomyopathy more than 5 months after delivery. Further research is necessary to understand whether there is a causal mechanism behind this association.

×